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Abstract 
Background: Bipolar depression is characterized by depressive symptoms and impairment in many areas of func-
tioning, including work, family, and social life. The objective of this study was to assess the independent, direct effect 
of lurasidone treatment on functioning improvement, and examine the indirect effect of lurasidone treatment on 
functioning improvement, mediated through improvements in depression symptoms.
Methods: Data from a 6-week placebo-controlled trial assessing the effect of lurasidone monotherapy versus pla-
cebo in patients with bipolar depression was used. Patient functioning was measured using the Sheehan disability 
scale (SDS). Descriptive statistics were used to assess the effect of lurasidone on improvement on the SDS total and 
domain scores (work/school, social, and family life), as well as number of days lost and unproductive due to symp-
toms. Path analyses evaluated the total effect (β1), as well as the indirect effect (β2×β3) and direct effect (β4) of lurasi-
done treatment on SDS total score change, using standardized beta path coefficients and baseline scores as covari-
ates. The direct effect of treatment on SDS total score change and indirect effects accounting for mediation through 
depression improvement were examined for statistical significance and magnitude using MPlus.
Results: In this 6-week trial (N = 485), change scores from baseline to 6-weeks were significantly larger for both 
lurasidone treatment dosage groups versus placebo on the SDS total and all three SDS domain scores (p < 0.05). 
Through path analyses, lurasidone treatment predicted improvement in depression (β2 = −0.33, p = 0.009), subse-
quently predicting improvement in functional impairment (β3 = 0.70, p < 0.001; indirect effect = −0.23). The direct 
effect was of medium magnitude (β4 = −0.17, p = 0.04), indicating lurasidone had a significant and direct effect on 
improvement in functional impairment, after accounting for depression improvement.
Conclusions: Results demonstrated statistically significant improvement in functioning among patients on lurasi-
done monotherapy compared to placebo. Improvement in functioning among patients on lurasidone was largely 
mediated through a reduction in depression symptoms, but lurasidone also had a medium and statistically significant 
independent direct effect in improving functioning.
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Background
Bipolar disorder is a chronic and debilitating mental ill-
ness characterized by recurrent episodes of hypomania, 
mania, and depressive symptoms (Goodwin and Jami-
son 2007). It is ranked by the World Health Organization 
as one of the top 20 causes of disability worldwide (Vos 
et al. 2012). The symptoms of bipolar disorder may often 
result in serious functional impairment and quality of 
life declines (Henry et al. 2013), primarily due to its early 
onset (approximately 18 years) and chronic nature.
In short-term clinical trials for the treatment of bipolar 
depression, the primary focus has traditionally focused 
on the alleviation of symptoms of bipolar depression. 
Remission of depressive symptoms is typically measured 
from clinician-reported outcome assessments of depres-
sion, such as a Montgomery–Asberg depression rating 
scale (MADRS) score ≤10 (Montgomery and Asberg 
1979) or a Hamilton rating scale for depression (HAM-
D) score ≤7 (Hamilton 1967). Since clinician-reported 
measures often do not capture treatment impact on func-
tional status, activities of daily living, or quality of life, 
all of which are areas that are important in the context 
of functional impairment for patients (Kessler et al. 2006; 
Miklowitz 2011; Harvey 2011; Greer et al. 2010), recent 
emphasis has been placed on patient-reported outcome 
measures to complement symptomatic assessments in 
this population (Rosa et  al. 2010). Indeed, some argue 
that patient-reported measures of psychosocial function-
ing that reflect how a patient feels or functions are more 
meaningful outcomes than clinician-reported measures 
of symptomatic remission (Keck 2004).
Given the important role of functional and quality of 
life parameters in determining the long-term effective-
ness of treatment, an understanding of the direct and 
indirect effect of drug treatment on functional improve-
ment is vital. Thus, this post hoc analysis of a placebo-
controlled monotherapy trial of lurasidone treatment 
among patients with bipolar depression was conducted 
to (1) describe the effect of lurasidone treatment on 
improvement in functional impairment (as measured 
by the SDS); and (2) examine the direct effect of lurasi-
done treatment on functional improvement, and assess 
the indirect effect (mediated through improvement in 
bipolar depression symptoms) of lurasidone in improving 
patient functioning.
Methods
Study design and data source
The 6-week, multicenter, randomized, double-blind, pla-
cebo-controlled, parallel-group bipolar depression mon-
otherapy trial of lurasidone was the data source for this 
analysis (NCT00868699). This trial has been described 
in detail in a previous publication (Loebel et  al. 2014b). 
Patients that completed the study at 6-weeks from a total 
of 505 randomized subjects receiving at least one dose of 
study medication at doses of 20–60 or 80–120  mg/day, 
with at least one baseline measurement of the MADRS 
and one post-baseline efficacy measurement for the 
MADRS formed the analytical sample (defined as the 
completer population). All patients were 18–75  years 
of age, experiencing a major depressive disorder (DSM-
IV-TR criteria, ≥4  weeks and <12  months in duration), 
with or without rapid cycling, without psychotic features, 
and with a history of at least one lifetime bipolar manic 
or mixed manic episode. The DSM-IV-TR diagnosis 
was confirmed via an interviewer-administered struc-
tured interview (Mini-International Neuropsychiatric 
Interview).
The study was approved by an institutional review 
board at each investigational site and was conducted in 
accordance with the International Conference on Har-
monisation of Good Clinical Practices guidelines and 
with the ethical principles of the Declaration of Helsinki.
Scales and assessments included in the analysis
Symptom assessment
Montgomery–Asberg depression rating scale (MADRS)
The patient’s primary bipolar depression symptoms were 
assessed using the MADRS, a clinician-administered rat-
ing scale developed from a larger scale to be sensitive to 
change (Montgomery and Asberg 1979). The MADRS 
has ten items, each scored on a 0–6 scale. A score of zero 
indicates an absence of that symptom, and anchor point 
descriptors are given for sores of 0, 2, 4, and 6. Items 
assess many facets of depression, including sadness, ten-
sion, pessimism, suicidal thoughts, reduced sleep, and 
reduced appetite. Higher scores indicate greater depres-
sion severity with a maximum total score of 60.
Functional impairment assessment
Sheehan disability scale (SDS)
Functional impairment was assessed using the Sheehan 
disability scale (SDS) (Sheehan et al. 1996; Sheehan and 
Sheehan 2008), a measure validated for use in patients 
with bipolar disorder (Arbuckle et al. 2009). The SDS is a 
composite of three self-rated items designed to measure 
the extent to which three major sectors in the subject’s 
life are impaired by panic, anxiety, phobic, or depres-
sive symptoms: work/school, social life, and family life. 
The three items are rated using an 11-point visual analog 
scale ranging from 0 to 10. In addition, two questions are 
used to assess the number of days lost due to symptoms 
and the number of days unproductive due to symptoms 
over the last week. The SDS total score is the sum of the 
three items and ranges from 0 (unimpaired) to 30 (highly 
impaired).
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Additional measures to characterize the patient 
population
In addition to the primary symptom and functional impair-
ment measures, three additional scales were also used to 
characterize the patient population. The Hamilton Anxiety 
Rating Scale (HAM-A) (Hamilton 1959) is a 14-item clini-
cian-rated assessment to measure the severity of anxiety 
symptoms. Each item is rated on a 5-point scale from 0 (not 
present) to 4 (severe/disabling), with a total score range of 
0–56. The quality of life satisfaction and enjoyment-short 
form (Q-LES-Q SF) is a 16-item health-related quality 
of life measure of the degree of enjoyment and satisfac-
tion experienced by patients in various areas of daily living 
(Endicott et  al. 1993). The 16 items reduce to eight sum-
mary scales that reflect major areas of functioning: physical 
health, mood, leisure time activities, social relationships, 
general activities, work, household duties, and school/
coursework. Each item is rated on a 5-point scale, rang-
ing from 1 (very poor) to 5 (very good). The sum of scores 
for items 1–14 can range from 14 to 70, and is expressed 
as a percentage (0–100) of the maximum total score that is 
achievable (items 15 and 16 were not used in the present 
analyses). Finally, the 16-Item quick inventory of depressive 
symptomology (QIDS-SR16) is a 16-item patient-reported 
outcome measure of depressive symptomology that con-
verts the responses to 16 items into the 9 DSM-IV symp-
tom criterion domains. Each item is rated on a 4-point 
scale, with higher scores indicative of greater symptomol-
ogy (total score range of 0–27) (Rush et al. 2003).
Statistical methods
Descriptive statistics
The demographic and baseline characteristics of all 
patients were summarized using descriptive statistics 
(mean, standard deviation, range, frequencies for cat-
egorical variables). In the clinical trial, efficacy assess-
ments were obtained at baseline and at weekly intervals, 
for up to 6-weeks, with the primary efficacy endpoint 
being a mean change in MADRS total score (∆MADRS) 
from baseline to 6-weeks (Loebel et  al. 2014b). For the 
current analysis, mean change in SDS total score (∆SDS 
total), individual domain scores (work/school, family life, 
social life), and the number of days lost and number of 
days unproductive from baseline to 6-weeks was used 
to describe the efficacy of treatment on improvement in 
functional impairment. Independent samples t-tests were 
conducted to assess for statistically significant differences 
in mean change scores between the lurasidone treatment 
groups versus placebo.
Path analysis
Path analysis was conducted (collapsing across dosage 
groups) to assess the relationship between treatment and 
∆SDS total score directly and through ∆MADRS and to 
quantify the total (direct and indirect) effects of treatment 
on improvement in functional impairment at 6-weeks, 
following the procedures described by Baron and Kenny 
(Baron and Kenny 1986). The Baron and Kenny media-
tion model was used to assess the degree of the treatment 
effect upon a response variable in the presence of another 
variable (i.e., the mediating variable). This approach 
allowed the examination of the degree of mediation 
(either as partial or complete mediation), through a series 
of four models. Statistically significant (p  <  0.05) effects 
must be obtained in Models 1, 2, and 3 in order to test the 
full mediation model in Model 4. Specifically, ∆MADRS 
would be considered a partial mediator if: (Model 1) 
treatment significantly predicts ∆SDS total; (Model 2) 
treatment significantly predicts ∆MADRS; (Model 3) 
independent of treatment, ∆MADRS linearly significantly 
predicts ∆SDS total; and (Model 4) treatment significantly 
predicts ∆SDS total, even when controlling for the effect 
of ∆MADRS. Complete mediation would be indicated if 
the effect of treatment on SDS described in Model 4 was 
0. Each of the models controlled for baseline score of the 
dependent variable (i.e., SDS total or MADRS).
Standardized parameter estimates with correspond-
ing p-values were calculated for all four models. The total 
effect (β1) of the relationship between treatment and ∆SDS 
total is estimated in Model 1. The direct effect of treat-
ment on the ∆SDS total controlling for ∆MADRS (β4), and 
the indirect effect, was estimated in Model 4. The indirect 
effect was calculated as the product of the relationship 
between treatment and ∆MADRS (β2), and the relation-
ship between ∆MADRS and ∆SDS total (β3). The propor-
tion of the effect that is mediated was calculated as β2×β3/
β1, while the percentage of total variance explained by each 
path was reported using the standardized R2 values.
The strength of the parameter estimates was inter-
preted using Kenny’s recommendations for estimates 
of small (0.02), medium (0.15), and large (0.40) (Kenny 
2014) effect sizes. Overall model fit was assessed using 
various global fit indices, where the following indices 
and fit values were used as criteria to assess acceptable 
model fit: Chi-square test of overall model fit; root mean 
square error of approximation (RMSEA) <0.06 (Mac-
Callum et  al. 1996); and Tucker–Lewis index (TLI) and 
the comparative fit index (CFI) >0.90 (Hu and Bentler 
1999). Mplus statistical software version 7.0 (Muthén and 




A total of 818 patients were screened, of whom 505 
(61.7 %) were randomly assigned to 6-weeks of treatment 
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and 280 (55.4  %) were included in the completer study 
population. Baseline demographic characteristics were 
similar for treatment (20–60 and 80–120  mg/day) and 
placebo groups, in addition to clinical characteristics, 
including clinician- and patient-completed assessments 
(Table  1). More extensive patient baseline characteris-
tics can be found in Loebel and colleagues (Loebel et al. 
2014b).
Changes in patient functioning outcomes
Descriptive statistics
Mean change scores for the SDS total and domain scores 
from baseline to 6-weeks are presented in Fig. 1. Change 
scores were significantly larger for both lurasidone dos-
age groups versus placebo on the SDS total and all three 
SDS domain scores. In addition, patients on lurasidone 
in both dosage groups and the combined dosage group 
reported a significantly fewer number of days lost and 
less unproductive days. Specifically, patients receiving 
lurasidone reported a mean change of −1.3 (SD =  2.2), 
−1.8 (SD = 2.4), and −1.6 (SD = 2.3) number of days lost 
for the lurasidone 20–60, 80–120 mg/day, and combined 
lurasidone treatment groups in comparison to −1.1 
(SD = 2.4) for placebo (all p < 0.001). Similarly, patients 
in all lurasidone treatment groups reported a mean 
change of −2.5 (SD = 2.8) days unproductive in compari-
son to −1.1 (SD = 2.7) for placebo (all p < 0.001).
Direct and indirect effects of lurasidone on improvement 
in functional impairment
Relationships tested in Models 1, 2, and 3 were statisti-
cally significant, thus, the full mediation model (Model 
4) was analyzed. Specifically, path analysis of Model 1 
revealed a moderate total effect for lurasidone treat-
ment predicting improvement in the SDS total score 
(β1  =  −0.40, p  =  0.001). Similarly, Models 2 and 3 
demonstrated moderate effects for the relationships 
between lurasidone treatment and improvement in 
MADRS (β = −0.41; p = 0.001), as well as improvement 
in MADRS on improvement in the SDS total score 
(β = 0.70; p < 0.001).
As shown in Fig. 2 depicting Model 4, treatment pre-
dicted improvement in MADRS (β2 = −0.33, p = 0.009), 
which subsequently predicted improvement in the SDS 
total score (β3 = 0.70, p < 0.001; indirect effect = −0.23). 
The direct effect was of medium magnitude and signifi-
cant (β4 = −0.17, p = 0.04), indicating partial mediation. 
Indirect and direct effects accounted for 57 and 43 % of 
the total effect, respectively. The full mediation model 
with indirect and direct effects explained 61.7  % of the 
variation in the change in the SDS total score.
Discussion
After 6-weeks, monotherapy lurasidone patients at a dose 
range of 20–120  mg/day performed significantly better 
and had greater reduction in functional impairment, as 
indicated by the SDS total score, compared to those on 
placebo. Similar change from baseline to 6-weeks was 
demonstrated across each of the SDS domain scores 
(work/school, family, and social life), indicating that all 
three domains contributed equally to the SDS total score 
improvement. Further, patients receiving all doses of lur-
asidone treatment also reported significantly fewer days 
lost and days unproductive due to symptoms in compari-
son to placebo. These domain-specific findings demon-
strate that at various dosage levels, lurasidone effectively 
improved functional impairment in patients with bipolar 
disorder in all areas of impairment assessed.
Previous research has demonstrated that lurasidone 
significantly improved symptoms of bipolar depres-
sion and functional impairment (Loebel et al. 2014a, b). 
The current analysis extends these findings by assess-
ing if improvement in functional impairment (SDS) due 
to lurasidone treatment was independent of improve-
ment in bipolar depression symptoms (MADRS). Path 
analysis revealed that improvement in SDS total scores 
was largely but not completely explained by improve-
ment in MADRS. The remaining statistically significant 
Table 1 Patient demographic characteristics of completer population at baseline (N = 280)
Lurasidone 20–60 mg/day (N = 90) Lurasidone 80–120 mg/day (N = 96) Placebo (N = 94)
Age, mean (SD) 41.2 (12.9) 41.7 (12.6) 39.1 (11.4)
Male, n (%) 43 (47.8 %) 41 (42.7 %) 44 (46.8 %)
White, n (%) 60 (66.7 %) 62 (64.6 %) 62 (66.0 %)
SDS total score, mean (SD) 10.1 (7.3) 10.0 (7.4) 13.3 (8.3)
MADRS total score, mean (SD) 29.9 (4.7) 29.7 (4.8) 29.8 (4.7)
HAM-A total score, mean (SD) 16.2 (6.6) 14.9 (4.9) 15.6 (6.1)
Q-LES-Q SF total score, mean (SD) 33.4 (13.8) 34.6 (12.8) 36.5 (13.2)
QIDS-SR16 total score, mean (SD) 14.0 (3.7) 14.3 (3.1) 14.5 (3.2)
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and medium-strength direct effect (β  =  −0.17), after 
accounting for the indirect effect of MADRS change on 
SDS total score change (57 % of the total effect), revealed 
that treatment had an independent effect on improve-
ment in functional impairment.
These findings are supported by a recent post hoc anal-
ysis of the original 485 patients included in the lurasi-
done efficacy analyses reported by Loebel and colleagues 
(Loebel et al. 2014b). In this post hoc analysis, Loebel and 
colleagues estimated rates of recovery, defined by com-
bined symptomatic remission (MADRS ≤12) and func-
tional remission (all SDS domain scores ≤3) sustained 
for at least 3 months in the 6-month continuation study, 
in patients treated with lurasidone monotherapy (Loe-
bel et  al. 2015). The proportion of lurasidone-treated 
patients attaining symptomatic remission (defined as 
a MADRS total score ≤12) at week 6 was significantly 
higher (40.9  %) compared to placebo (24.7  %, p  <  0.01) 
(Loebel et  al. 2015). Similarly, the proportion of lurasi-
done-treated patients achieving functional remission 
at week 6 was significantly higher (48.4 %) compared to 
placebo (31.5 %, p < 0.01). However, as the current analy-
sis utilized path analysis to assess for direct and indirect 
effects of treatment, it is impossible to rule out potential 
pseudo-specific effects on the patient’s report of func-
tioning improvement.
The clinical importance of these findings is supported 
by a body of research that has documented the value of 
assessing functional impairment as a disability endpoint 
in this population. Multiple investigations have dem-
onstrated that patients with bipolar depression are sig-
nificantly more likely to report impairment in functional 
areas valued by patients, including relationships with 
family and friends, functioning at work and school, and 
cognitive impairment (Keck 2004; Rosa et  al. 2010; Alt-
shuler et  al. 2006; Tohen et  al. 2000; Simon et  al. 2007; 
Henry et  al. 2013; Depp et  al. 2012; Gutierrez–Rojas 
et al. 2011; Calabrese et al. 2004). Further, even patients 
in remission from depressive symptoms may show con-
tinued, impaired psychosocial functioning (Rosa et  al. 
2010; Greer et al. 2010), demonstrating the need to assess 
functional impairment even in the absence of continued 
depressive symptoms. Thus, patient-centered assessment 
tools such as the SDS are valuable for measuring change 
in functional and disability outcomes important to 
patients with bipolar disorder that may not be captured 
using clinician-completed symptom assessments such 
as the MADRS. Our findings support the need for inde-
pendent assessment patient functional improvement as 
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Fig. 1 Mean change for SDS total (a) and domain (b) scores from 
baseline to 6-weeks by treatment group. Lurasidone vs. Placebo: 
















Fig. 2 Full Mediation Model. RMSEA root mean square error of approximation; CFI comparative fit index; TLI Tucker–Lewis index; Indirect, percentage 
of change in SDS variance explained by indirect effects; Direct, percentage of change in SDS variance explained by direct effect
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or antidepressant treatment. However, it should be noted 
that although the SDS was developed for the assessment 
of functional impairment in clinical trials of depression, 
anxiety, and bipolar disorders, the SDS is often found 
to be moderately correlated with measures of depres-
sion. Indeed, in the present study, the SDS Total score 
was found to be moderately correlated with the MADRS 
(r = 0.37). Thus, the findings of the present study are pre-
liminary, as no clinician- or performance-based assess-
ment of functional impairment was available to use to 
confirm the patient’s report of improvement in function-
ing specifically.
Although treatment remained a statistically significant 
predictor of improvement in functional impairment, 
changes in bipolar depression symptoms accounted for 
the majority of the effect on change in functional impair-
ment. As has been elaborated by the FDA PRO guidance 
document (Food and Drug Administration 2009), a well-
validated PRO should be able to measure the effects of 
a treatment on “how a patient feels or functions” both 
through the direct and mediated effect on symptom 
improvements. The findings of this analysis are con-
sistent with previous work that has demonstrated that 
mood symptoms (such as depression) may actually be 
independent predictors of functioning in patients with 
bipolar depression (Burdick et al. 2010) or major depres-
sive disorder (Sheehan et al. 2011; Wise et al. 2008). For 
example, Sheehan and colleagues (Sheehan et  al. 2011), 
using the SDS to assess functional outcomes, conducted 
multivariate lead-lag regression analyses to demonstrate 
that changes in mood and depressive symptoms at weeks 
6 and 7 (during an episode or in a treatment trial) were 
significantly correlated with changes in the SDS total 
score at week 8, indicating that changes in mood symp-
toms associated with treatment significantly predicted 
change in functional outcomes. Using a causal mod-
eling approach in the current study, our findings sup-
ported those of Sheehan and colleagues, as improvement 
in symptoms of bipolar depression, in turn, resulted in 
improvement in functional impairment.
The findings from the mediation analysis have particu-
lar clinical importance as it relates to the treatment of 
individuals with bipolar depression. Specifically, it is pos-
sible to reduce disability and functional impairment, in 
conjunction with symptomatic remission with the same 
treatment. Indeed, Simon and colleagues (Simon et  al. 
2007) conducted a secondary analysis of a 12-month ran-
domized trial of a care management and psychoeduca-
tional intervention for bipolar disorder. These researchers 
found that within-person improvement in depression 
severity due to treatment was associated with clinically 
significant improvement in impairment and disability. 
While some researchers advocate for interventions that 
specifically target improvement in functional outcomes 
(Rosa et  al. 2010), our findings provide preliminary evi-
dence for an efficient treatment that has been demon-
strated to improve function, both mediating through and 
independently from a reduction in depressive symptoms. 
However, further research using a causal study design is 
needed to confirm these findings.
Several study limitations should be noted. First, this 
study was a post hoc analysis of a short-term acute trial. 
A longitudinal study is needed to confirm that patients 
maintained these improvements over a longer period 
of time, and to determine if the mediating effect of 
depressive symptom severity improvement on reduced 
functional impairment persists. Second, functional 
impairment was assessed based on patient-reported data 
of patients that had not yet achieved remission status, 
and not through direct observation of patient behavior 
and functioning. Similar to many registration clinical tri-
als facing limited resource issues, functional impairment 
was measured by the SDS as one of the secondary end-
points, and our clinical trial did not employ additional 
informant assessment such as clinician-reported meas-
ures of functioning or performance-based assessments to 
validate the self-reported functioning outcomes. Along 
the same lines, no neuropsychological measures were 
administered to further understand the psychological 
functioning of the patient population at baseline or study 
completion. Thus, our analyses and the conclusions that 
can be drawn in our study are exploratory in nature and 
need further confirmation from future investigations. 
Finally, in regards to the path analysis, our sample size 
was limited and our tested models should be re-estimated 
in a larger population, whenever possible in future stud-
ies. While mediation analyses allow for the interpretation 
of a causal association between constructs, these findings 
are preliminary and further analysis using a causal study 
design will help to substantiate the current findings that 
changes in bipolar depression were causally associated 
with changes in functional impairment.
Conclusions
In conclusion, the findings from the present study indi-
cate that lurasidone as a monotherapy is efficacious in 
improving functional impairment in patients with bipolar 
depression, in addition to reducing depressive symptoms. 
Lurasidone largely improved functional impairment indi-
rectly through reductions in depressive symptoms, with 
a smaller effect evidenced directly between treatment 
and improved functional impairment. These findings 
underscore the need for patient-reported outcomes to 
complement clinician-reported measures in understand-
ing the value of treatment for patients. This analysis fur-
ther illustrates the importance of treatment selection in 
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addressing patient-centered issues relating to symptoma-
tology and functional improvement in chronic mental ill-
nesses such as bipolar disorder.
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